New insider activity at Teva Pharmaceutical ( (TEVA) ) has taken place on March 19, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Teva Pharmaceutical’s Executive Vice President for International Markets Commercial, Mark Sabag, has sold 62,102 shares of Teva Pharmaceutical stock in a transaction valued at $1,871,754, signaling a notable insider move at the company.
Spark’s Take on TEVA Stock
According to Spark, TipRanks’ AI Analyst, TEVA is a Neutral.
The score is driven primarily by improving fundamentals (return to profitability and solid free cash flow) but constrained by elevated leverage and historical volatility. Technicals are supportive with strong uptrend momentum, while valuation is a headwind at a ~27 P/E and no dividend yield. Earnings-call guidance is constructive on margins, growth brands, and deleveraging, but near-term revenue and quarterly volatility risks cap the upside.
To see Spark’s full report on TEVA stock, click here.
More about Teva Pharmaceutical
YTD Price Performance: -5.13%
Average Trading Volume: 9,121,852
Technical Sentiment Signal: Buy
Current Market Cap: $34.84B